Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 35 articles:
HTML format
Text format



Single Articles


    June 2018
  1. KURLAND BF, Oesterreich S
    Heterogeneity in metastatic breast cancer (18)F-fluoroestradiol uptake - clinically actionable, biologically illuminating?
    J Nucl Med. 2018 Jun 14. pii: jnumed.118.214304. doi: 10.2967/jnumed.118.214304.
    PubMed     Text format    


  2. SAH BR, Ghafoor S, Burger IA, Ter Voert EEGW, et al
    Feasibility of (18)F-FDG Dose Reductions in Breast Cancer PET/MRI.
    J Nucl Med. 2018 Jun 7. pii: jnumed.118.209007. doi: 10.2967/jnumed.118.209007.
    PubMed     Text format     Abstract available


    May 2018
  3. PETERSON LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, et al
    Prospective study of serial (18)F-FDG PET and (18)F-fluoride ((18)F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer.
    J Nucl Med. 2018 May 10. pii: jnumed.118.211102. doi: 10.2967/jnumed.118.211102.
    PubMed     Text format     Abstract available


    April 2018
  4. WU J, Wang S, Zhang X, Teng Z, et al
    (18)F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study.
    J Nucl Med. 2018 Apr 26. pii: jnumed.118.208637. doi: 10.2967/jnumed.118.208637.
    PubMed     Text format     Abstract available


  5. GROHEUX D
    Now is the time to use FDG-PET/CT to optimize neoadjuvant treatment in triple negative breast cancer!
    J Nucl Med. 2018 Apr 19. pii: jnumed.118.210922. doi: 10.2967/jnumed.118.210922.
    PubMed     Text format    


    March 2018
  6. NIENHUIS HH, van Kruchten M, Elias SG, Glaudemans AWJM, et al
    ((18))F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846.
    PubMed     Text format     Abstract available


  7. MONTEMAGNO C, Bacot S, Ahmadi M, Kerfelec B, et al
    Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer.
    J Nucl Med. 2018 Mar 23. pii: jnumed.117.203489. doi: 10.2967/jnumed.117.203489.
    PubMed     Text format     Abstract available


    February 2018
  8. HUMBERT O, Lasserre M, Bertaut A, Fumoleau P, et al
    Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition (18)FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.
    J Nucl Med. 2018 Feb 9. pii: jnumed.117.203075. doi: 10.2967/jnumed.117.203075.
    PubMed     Text format     Abstract available


    November 2017
  9. ULANER GA, Lyashchenko SK, Riedl C, Ruan S, et al
    First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.
    J Nucl Med. 2017 Nov 16. pii: jnumed.117.202010. doi: 10.2967/jnumed.117.202010.
    PubMed     Text format     Abstract available


    September 2017
  10. VENEMA CM, Mammatas LH, Schroder CP, van Kruchten M, et al
    Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies.
    J Nucl Med. 2017 Sep 14. pii: jnumed.117.193649. doi: 10.2967/jnumed.117.193649.
    PubMed     Text format     Abstract available


    August 2017
  11. HENRY KE, Dilling TR, Abdel-Atti D, Edwards KJ, et al
    Non-invasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared to 18F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.
    J Nucl Med. 2017 Aug 28. pii: jnumed.117.192286. doi: 10.2967/jnumed.117.192286.
    PubMed     Text format     Abstract available


  12. PAQUETTE M, Lavallee E, Phoenix S, Ouellet R, et al
    Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 4FMFES in ER+ Breast Cancer Patients: an Ongoing Phase II Clinical Trial.
    J Nucl Med. 2017 Aug 10. pii: jnumed.117.194654. doi: 10.2967/jnumed.117.194654.
    PubMed     Text format     Abstract available


    June 2017
  13. MORTIMER JE, Bading JR, Park JM, Frankel PH, et al
    Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.193888. doi: 10.2967/jnumed.117.193888.
    PubMed     Text format     Abstract available


    April 2017
  14. AHRENS BJ, Li L, Ciminera AK, Chea J, et al
    Diagnostic PET Imaging of Mammary Microcalcifications using 64Cu-DOTA-alendronate in a Rat Model of Breast Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.190850. doi: 10.2967/jnumed.117.190850.
    PubMed     Text format     Abstract available


  15. DALM SU, Haeck J, Doeswijk GN, de Blois E, et al
    SSTR-mediated Breast Cancer Imaging: Is There A Role For Radiolabeled SSTR Antagonists?
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.189035. doi: 10.2967/jnumed.116.189035.
    PubMed     Text format     Abstract available


  16. DONOHOE KJ, Cohen EJ, Giammarile F, Grady E, et al
    Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts.
    J Nucl Med. 2017;58:14N-17N.
    PubMed     Text format    


  17. GROHEUX D
    18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer.
    J Nucl Med. 2017;58:683.
    PubMed     Text format    


    March 2017
  18. MORGAT C, MacGrogan G, Brouste V, Velasco V, et al
    Expression of Gastrin-Releasing Peptide Receptor (GRPR) in Breast Cancer and its Association with Pathological, Biological and Clinical Parameters: A Study of 1432 Primary Tumors.
    J Nucl Med. 2017 Mar 9. pii: jnumed.116.188011. doi: 10.2967/jnumed.116.188011.
    PubMed     Text format     Abstract available


    January 2017
  19. LI L, Wu Y, Wang Z, Jia B, et al
    SPECT/CT Imaging of the Novel HER2-targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.183863. doi: 10.2967/jnumed.116.183863.
    PubMed     Text format     Abstract available


    December 2016
  20. CHAE SY, Kim SB, Ahn SH, Moon DH, et al
    Reply: 18F-fluoroestradiol positron emission tomography to predict response to neoadjuvant treatment in luminal breast cancer.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.185660.
    PubMed     Text format    


    November 2016
  21. FOWLER AM, Linden HM
    Functional Estrogen Receptor Imaging Prior to Neoadjuvant therapy for Primary Breast Cancer.
    J Nucl Med. 2016 Nov 17. pii: jnumed.116.183533.
    PubMed     Text format    


    October 2016
  22. YANG H, Jenni S, Colovic M, Merkens H, et al
    18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models.
    J Nucl Med. 2016 Oct 27. pii: jnumed.116.180661.
    PubMed     Text format     Abstract available


    September 2016
  23. CHAE SY, Kim SB, Ahn SH, Kim HO, et al
    A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.178368.
    PubMed     Text format     Abstract available


  24. LEBON V, Alberini JL, Pierga JY, Dieras V, et al
    The rate of distant metastases on FDG-PET/CT at initial staging of breast cancer: comparison between women younger and older than 40 years.
    J Nucl Med. 2016 Sep 1. pii: jnumed.116.178749.
    PubMed     Text format     Abstract available


    June 2016
  25. DOOT RK
    Invited Perspective for: 18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer.
    J Nucl Med. 2016 Jun 3. pii: jnumed.116.175687.
    PubMed     Text format    


    May 2016
  26. MCCONATHY J
    [F-18]Fluciclovine (FACBC) and its Potential Use for Breast Cancer Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.116.175489.
    PubMed     Text format    


  27. LIN CY, Lin CL, Kao CH
    Reply: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 19. pii: jnumed.116.178152.
    PubMed     Text format    


  28. ULANER GA, Hyman D, Ross D, Corben A, et al
    Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT.
    J Nucl Med. 2016 May 5. pii: jnumed.115.172031.
    PubMed     Text format     Abstract available


  29. CHEN KT, Hu YW
    Letter: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 5. pii: jnumed.116.173641.
    PubMed     Text format    


    February 2016
  30. VAN ES SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, et al
    Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.
    J Nucl Med. 2016;57 Suppl 1:96S-104S.
    PubMed     Text format     Abstract available


  31. GEBHART G, Flamen P, De Vries EG, Jhaveri K, et al
    Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.
    J Nucl Med. 2016;57 Suppl 1:81S-8S.
    PubMed     Text format     Abstract available


  32. BERG WA
    Nuclear Breast Imaging: Clinical Results and Future Directions.
    J Nucl Med. 2016;57 Suppl 1:46S-52S.
    PubMed     Text format     Abstract available


  33. HSU DF, Freese DL, Levin CS
    Breast-Dedicated Radionuclide Imaging Systems.
    J Nucl Med. 2016;57 Suppl 1:40S-5S.
    PubMed     Text format     Abstract available


  34. WAHL RL
    Quo Vadis: PET and Single-Photon Molecular Breast Imaging.
    J Nucl Med. 2016;57 Suppl 1:3S-8S.
    PubMed     Text format    


  35. CZERNIN J, Mankoff D
    Introduction and Overview.
    J Nucl Med. 2016;57 Suppl 1:1S-2S.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: